The Ministry of Industry and Information Technology of China has released a document titled "Six Dos and Don'ts for Preventing Security Risks of OpenClaw (Lobster) Open Source Intelligent Agents," which outlines the typical application scenario security risks of OpenClaw, including: the smart office scenario mainly has prominent risks of supply chain attacks and intrusions into the corporate intranet; the development and operation scenario mainly has prominent risks of sensitive information leakage of system devices and being hijacked; the personal assistant scenario mainly has prominent risks of personal information theft and sensitive information leakage; the financial transaction scenario mainly has prominent risks of triggering erroneous transactions or even account takeover.
In addition, it points out six usage recommendations: use the official latest version; strictly control the internet exposure; adhere to the principle of least privilege; use the skill market with caution; guard against social engineering attacks and browser hijacking; establish a long-term protection mechanism.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.


















Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.











